ALZN · Alzamend Neuro, Inc.
$1.25
-0.05 (-3.85%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Sep 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors create substantial doubt about our ability to continue as a going concern for at least one year after the date that our condensed financial statements are issued.”View the 10-Q filed Sep 10, 2026
Market Cap
$6.49M
Shares
4.83M
Volume · Oct 21
10.56K
Avg daily vol (3M)
81K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.25
Open$1.29
Day$1.25–1.39
52W close$0.86–2.61
Avg vol 30d81K
Short int112K · 2.3% float · 1.1d
Short vol19%
DataJun 2021–Oct 2026
Filing10-Q · Sep 10
Up next
filed Sep 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$9.10M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$7.59M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+112.7%
Year over year · more shares
Price change (1Y)
-44.7%
Trailing year
Short interest
2.3%
Latest settlement · 1.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−18%
below
Price vs 50-day avg
−21%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
22%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−36%
trailing
6-month return
+10%
trailing
YTD return
−31%
this year
Relative strength
+2%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
2 of 12 funds reported for Sep 30 · net -209.2K sh shares
Insider flow
Distributing
Net -$3.1K over 90 days · 100% sells
Short interest
Falling
2.31% of float · ▼ -9.3% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 3-yr range
Squeeze score
36
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−67%
past year
ATR
8.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−18%
Bearish
Price vs 50-day avg
−21%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
22%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
2 of 12 funds reported for Sep 30 · net -209.2K sh shares
Insider flow
Distributing
Net -$3.1K over 90 days · 100% sells
Short interest
Falling
2.31% of float · ▼ -9.3% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 22%
Range high $3
vs 200-day avg -18%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALZN
this stock
Alzamend Neuro, Inc.
|
$6.49M | -31.3% | — | — | 2.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.39B | +15.7% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +733.5% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.4% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.22B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALZN | -7.4% | -35.6% | +9.7% | -27.8% | -31.3% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | -7.9% | -36.3% | +2.1% | -29.1% | -44.7% |